News

Filter

Current filters:

None

Popular Filters

1 to 25 of 8856 results

Harlan aims to provide expertise for biologics and biosimilars

31-07-2014

Switzerland-based Harlan Laboratories, a privately held provider of general and specialty toxicology…

BiosimilarsBiotechnologyContract research servicesHarlanRegulationResearchSwitzerlandToxicology services

Janssen’s simeprevir for hepatitis C shows good efficacy in Phase II trial

Janssen’s simeprevir for hepatitis C shows good efficacy in Phase II trial

31-07-2014

Some 92% of genotype 1 chronic hepatitis C virus (HCV) adult patients treated with US health care giant…

Anti-viralsGilead SciencesIrelandJanssenPharmaceuticalResearchsimeprevirsofosbuvir

Valeant's revenue jumps 86% to hit $2 billion

Valeant's revenue jumps 86% to hit $2 billion

31-07-2014

Canadian pharma company Valeant, which is currently attempting a takeover of Allergan, reported a 12-fold…

AllerganBausch & LombCanadaFinancialPharmaceuticalValeantValeant Pharmaceuticals

Albumin sales to play major part in growth of billion-dollar critical care market

Albumin sales to play major part in growth of billion-dollar critical care market

31-07-2014

The critical care market across eight major countries will grow to $2.5 billion by 2020, according to…

AlbuminBlood proteinsGlobalMarkets & MarketingPharmaceutical

AstraZeneca 2nd-qtr earnings leap, beating expectations

AstraZeneca 2nd-qtr earnings leap, beating expectations

31-07-2014

Anglo-Swedish pharma major AstraZeneca, which earlier this year defended itself against an unsolicited…

AstraZenecaBusiness FinanceFinancialPharmaceuticalUK

Meda in $3.1 billion deal to acquire Italy’s Rottapharm

Meda in $3.1 billion deal to acquire Italy’s Rottapharm

31-07-2014

Sweden’s Meda says it has entered into a definitive agreement to acquire Rottapharm Madaus, an Italian…

Business FinanceItalyMedaMergers & AcquisitionsMergers and acquisitionsPharmaceuticalRottapharm MadausSwedenSweden

Novartis' KAE609 effective in uncomplicated malaria patients

Novartis' KAE609 effective in uncomplicated malaria patients

31-07-2014

Swiss drug major Novartis says that results published in the New England Journal of Medicine show that…

Antibiotics and Infectious diseasesJoseph JimenezKAE609NovartisPharmaceuticalPlasmodiumResearchSwitzerland

NICE consulting again on Celgene's Revlimid for multiple myeloma

NICE consulting again on Celgene's Revlimid for multiple myeloma

31-07-2014

The UK clinical guidance body, the National Institute for Health and Care Excellence (NICE), is again…

Celgene Corp.ImmunosuppressantslenalidomideOncologyPharmaceuticalRegulationRevlimidUK

Sanofi posts strong 2nd-qtr earnings, beating estimates

Sanofi posts strong 2nd-qtr earnings, beating estimates

31-07-2014

French pharma major Sanofi this morning reported that group sales for the second quarter of 2014 grew…

FinancialFranceGaucherGenzymeInsulin glargineMajorMiddle EastPharmaceuticalSanofi

Pfizer spends $635 million on acquiring two Baxter vaccines

Pfizer spends $635 million on acquiring two Baxter vaccines

30-07-2014

US pharma giant Pfizer has entered into a definitive agreement to acquire Baxter International portfolio…

Baxter InternationalMergers & AcquisitionsPfizerPharmaceuticalProductionUSAVaccines

Regeneron’s Eylea gains FDA approval for DME

Regeneron’s Eylea gains FDA approval for DME

30-07-2014

The Food and Drug Administration has approved US biotech firm Regeneron Pharmaceuticals’ Eylea (aflibercept)…

BayerBiotechnologyEyleaOphthalmicsRegeneronRegulationUSA

New indications approved in EU for Bristol-Myers/Pfizer Eliquis

New indications approved in EU for Bristol-Myers/Pfizer Eliquis

30-07-2014

The European Commission has approved US pharma majors Bristol-Myers Squibb and Pfizer’s Eliquis (apixaban)…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalRegulation

Durata out-licenses dalbavancin to Angelini for certain territories

Durata out-licenses dalbavancin to Angelini for certain territories

30-07-2014

USA-based Durata Therapeutics says its Dutch subsidiary entered into a license and supply agreement with…

AngeliniAntibiotics and Infectious diseasesDalvanceDurata TherapeuticsEuropeLicensingPharmaceutical

Cellectis sells Swedish subsidiary to Japan’s Takara Bio

30-07-2014

France-based genome engineering specialist Cellectis says it has sold its Swedish subsidiary Cellectis…

BiotechnologyBusiness FinanceCellectisCellectis ABFranceMergers & AcquisitionsTakara Bio

Sanofi and Regneron say Phase III alirocumab trials met primary endpoint

Sanofi and Regneron say Phase III alirocumab trials met primary endpoint

30-07-2014

French drug major Sanofi and USA-based biotech firm Regeneron Pharmaceuticals have announced that nine…

alirocumabCardio-vascularGeorge YancopoulosPharmaceuticalResearchSanofiUSA

Bayer’s 2nd-qtr earnings hit by currency, missing expectations

Bayer’s 2nd-qtr earnings hit by currency, missing expectations

30-07-2014

Germany’s pharma and life sciences major Bayer posted a solid set of second-quarter 2014 financial…

BayerCancerConsumer HealthFinancialGermanyGermanyPharmaceuticalPulmonary hypertension

Ranbaxy down on same quarter last year following FDA fine

Ranbaxy down on same quarter last year following FDA fine

30-07-2014

Indian generic pharma company Ranbaxy, has reported consolidated sales of 23.7 billion rupees ($394 million),…

BSE SensexFinancialGenericsIndiaOver-the-counter accountingPharmaceutical industryRanbaxyRanbaxy Laboratories

AstraZeneca and Kyowa Hakko Kirin sign immunotherapy research deal

AstraZeneca and Kyowa Hakko Kirin sign immunotherapy research deal

30-07-2014

Anglo-Swedish pharma major AstraZeneca today announced that it has entered into a clinical study collaboration…

AstraZenecaBriggs MorrisonImmunologyJapanKyowa Hakko KirinOncologyPharmaceuticalResearchUK

1 to 25 of 8856 results

Back to top